サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405841

先端巨大症治療の市場規模、シェア、動向分析レポート：薬物タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年

Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Type (Somatostatin Analogs, GHRA), By End-use (Hospitals & Clinics), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
先端巨大症治療の市場規模、シェア、動向分析レポート：薬物タイプ別、最終用途別、地域別、セグメント予測、2023年～2030年
出版日: 2023年12月11日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

先端巨大症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の先端巨大症治療市場規模は2023年から2030年にかけてCAGR 5.7%で拡大し、2030年には19億3,000万米ドルに達する見込みです。

先端巨大症の罹患率の増加が成長を促進すると予想されています。例えば、内分泌学会の報告書によると、2015年の疾患有病率は前年の2014年から4倍に増加しました。さらに、さまざまな製薬会社が新しい分子を開発するために臨床試験への投資を拡大していることも、市場の成長を後押しする要因となっています。

さらに、薬剤の強力なパイプラインは、今後数年間で成長機会を生み出すと予想されています。例えば、Chiasma Inc.のMycapssaは2016年に欧州で承認を取得しました。2018年には、Antisense Therapeutics社が米国で新製剤ALT1103を発売しました。成長ホルモン受容体拮抗薬であるIonis Pharmaceuticals Inc.社のISIS 766720は現在第II相臨床試験中であり、2019年12月までに終了する見込みです。

ソマトスタチン類似体の強力なパイプラインは、近い将来、先端巨大症治療薬市場の成長を促進すると期待されています。例えば、2018年には北米で約30件の臨床試験が実施され、多くが米国食品医薬品局（FDA）の承認を待っています。

先端巨大症治療市場レポートハイライト

  • ソマトスタチン類似体セグメントは、同製品の容易な入手可能性と費用対効果の高い治療手順により、今後数年間、収益シェアで最大の製品セグメントとして浮上すると予想されます。
  • 病院・診療所最終用途セグメントは、すべての外科手術がこれらの施設で行われるため、最大の市場シェアを占める。外科医が容易に利用できることが、このセグメントをさらに牽引すると予想されます。
  • 北米は、有利な政府保険政策と製薬会社による研究開発投資の増加により、2022年に圧倒的な市場シェアを占めました。例えば、2018年5月、米国議会は、先端巨大症のような希少疾病を含む重篤な病気の場合、患者が未検証の医療治療薬を試すことができる「Right to Try法案」を承認しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 先端巨大症治療市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 先端巨大症治療市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 先端巨大症治療市場：薬物タイプの推定・動向分析

  • 先端巨大症治療市場：重要なポイント
  • 先端巨大症治療市場：薬剤タイプの動向と市場シェア分析、2022年および2030年
  • ソマトスタチン類似体
    • 市場推計・予測、2018年から2030年まで
  • GHRA
    • 市場推計・予測、2018年から2030年まで
  • その他
    • 市場推計・予測、2018年から2030年まで

第5章 先端巨大症治療市場：最終用途の推定・動向分析

  • 先端巨大症治療市場：重要なポイント
  • 先端巨大症治療市場：最終用途の動きと市場シェア分析、2022年と2030年
  • 病院とクリニック
    • 市場推計・予測、2018年から2030年まで
  • その他
    • 市場推計・予測、2018年から2030年まで

第6章 先端巨大症治療市場：地域の推定・動向分析

  • 地域別の見通し
  • 地域別先端巨大症治療市場：マーケットプレースにおける重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Novartis AG
    • Ipsen Pharma
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • Chiasma, Inc.
    • Peptron, Inc.
    • WOCKHARDT
    • Dauntless Pharmaceuticals
    • Pfizer Inc.
    • Ionis Pharmaceuticals, Inc.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 4 North America acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 6 U.S. acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 8 Canada acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Europe acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Germany acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 15 UK acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 France acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 19 Italy acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 21 Spain acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Sweden acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 Sweden acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Norway acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 25 Norway acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Denmark acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 27 Denmark acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 China acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 China acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 Japan acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 36 India acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Australia acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Thailand acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 40 Thailand acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 South Korea acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 South Korea acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 44 Latin America acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 47 Brazil acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 49 Mexico acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 Argentina acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa acromegaly treatment market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 56 South Africa acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 UAE acromegaly treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait acromegaly treatment market, by drug type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait acromegaly treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research processes
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Acromegaly treatment: Market outlook
  • Fig. 9 Acromegaly treatment: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Acromegaly treatment market driver impact
  • Fig. 15 Acromegaly treatment market restraint impact
  • Fig. 16 Acromegaly treatment market strategic initiatives analysis
  • Fig. 17 Acromegaly treatment market: Drug type movement analysis
  • Fig. 18 Acromegaly treatment market: Drug type outlook and key takeaways
  • Fig. 19 Somatostatin analogs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 GHRA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Acromegaly treatment market: End use movement analysis
  • Fig. 23 Acromegaly treatment market: End use outlook and key takeaways
  • Fig. 24 Hospital & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Global acromegaly treatment market: Regional movement analysis
  • Fig. 27 Global acromegaly treatment market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-3-68038-053-8

Acromegaly Treatment Market Growth & Trends:

The global acromegaly treatment market size is expected to reach USD 1.93 billion by 2030, expanding at a CAGR of 5.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

Acromegaly Treatment Market Report Highlights:

  • Somatostatin analogs segment is expected to emerge as the largest product segment in terms of revenue share in the forthcoming years, owing to easy availability and cost-effective treatment procedure of the product
  • Hospital and clinics end use segment accounted for the largest market share as all the surgical procedures are performed in these facilities. Easy availability of surgeons Is anticipated to further drive the segment
  • North America held the dominant market share in 2022, due to favorable government insurance policies and increased investment in R&D by the pharmaceutical companies. For instance, In May 2018, U.S. Congress approved the Right to Try bill, wherein patients can try unproven medical therapeutics in case of serious illness including orphan diseases like acromegaly

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Acromegaly Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Acromegaly Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Acromegaly Treatment Market: Drug Type Estimates & Trend Analysis

  • 4.1. Acromegaly Treatment Market: Key Takeaways
  • 4.2. Acromegaly Treatment Market: Drug Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Somatostatin analogs
    • 4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. GHRA
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Acromegaly Treatment Market: End-use Estimates & Trend Analysis

  • 5.1. Acromegaly Treatment Market: Key Takeaways
  • 5.2. Acromegaly Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals & Clinics
    • 5.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Others
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Acromegaly Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Acromegaly Treatment Market by Region: Key Marketplace Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Novartis AG
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Ipsen Pharma
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Chiasma, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Peptron, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. WOCKHARDT
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Dauntless Pharmaceuticals
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Pfizer Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Ionis Pharmaceuticals, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives